<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00967070</url>
  </required_header>
  <id_info>
    <org_study_id>A6431084</org_study_id>
    <nct_id>NCT00967070</nct_id>
  </id_info>
  <brief_title>Skin Sensitization Potential of a New Nicotine Patch</brief_title>
  <official_title>Study on the Skin Sensitization Potential of a New Nicotine Transdermal Therapeutic System (TTS). A Double Blind, Randomized, Repeat Patch Test, Single Center Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McNeil AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Consumer and Personal Products Worldwide</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An investigation on the skin sensitization potential of a new nicotine patch. Evaluation of&#xD;
      the potential of a new nicotine transdermal patch to cause sensitization in the skin after&#xD;
      repeated applications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study on the skin sensitization potential of a new nicotine transdermal therapeutic system&#xD;
      (TTS). A double blind, randomized, repeat patch test, single center phase I study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Individual Irritation Scores</measure>
    <time_frame>15 or 30 min, and 24, 48, and 72 hr post-application, depending on trial phase</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Individual Irritation Score (IIS)</measure>
    <time_frame>15 or 30 min, and 24, 48, and 72 hr post-application, depending on trial phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patch adhesion score</measure>
    <time_frame>directly before patch removal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>at each visit</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">257</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Both Treatments Applied on Lower Back</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatments were applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine Patch</intervention_name>
    <description>25 mg nicotine patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.</description>
    <arm_group_label>Both Treatments Applied on Lower Back</arm_group_label>
    <other_name>Experimental Nicotine Patch</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Patch</intervention_name>
    <description>Placebo patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.</description>
    <arm_group_label>Both Treatments Applied on Lower Back</arm_group_label>
    <other_name>Placebo Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and female subjects between 18 and 65 years&#xD;
&#xD;
          -  Heavy smokers (more than 10 cigarettes per day)&#xD;
&#xD;
          -  Having had no febrile or infectious illness for at least seven days prior to the first&#xD;
             administration of the investigational product.&#xD;
&#xD;
          -  Women practicing one or a combination of the following methods of birth control:&#xD;
             hormonal contraceptives, condoms, sponge, foams, jelly, diaphragm, or intrauterine&#xD;
             device or women who are surgically sterilized.&#xD;
&#xD;
          -  Subjects having normal skin without excessive hair growth on tested areas.&#xD;
&#xD;
          -  Evidence of a personally signed and dated informed consent document indicating that&#xD;
             the subjects has been informed of all pertinent aspects of the trial.&#xD;
&#xD;
          -  Subjects who are willing to comply with scheduled visits, treatment plan and other&#xD;
             trial procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any visible skin disorder or abnormal skin pigmentation which, in the opinion of the&#xD;
             investigator, would interfere with the outcome of the trial&#xD;
&#xD;
          -  Dermatologic disease that might interfere with the evaluation of the test site&#xD;
             reaction&#xD;
&#xD;
          -  History of chronic, dermatological, medical, or physical conditions which would, in&#xD;
             the opinion of the investigator, preclude topical application of the test products&#xD;
             and/or influence the outcome of the test (in particular, any immunosuppressive&#xD;
             condition)&#xD;
&#xD;
          -  Clinically relevant abnormal findings on the physical examination&#xD;
&#xD;
          -  A baseline score in skin reaction assessments other than &quot;0&quot; on the areas to be&#xD;
             patched&#xD;
&#xD;
          -  Pregnant (verified by beta-hCG-test in urine) and/or nursing women&#xD;
&#xD;
          -  Demonstrating any active physical disease, acute or chronic&#xD;
&#xD;
          -  Any suspicion, history or evidence of alcohol or drug abuse&#xD;
&#xD;
          -  Any history of drug hypersensitivity, asthma, urticaria or other severe allergic&#xD;
             diathesis as well as current hay fever&#xD;
&#xD;
          -  Any current or past history of chronic or recurrent metabolic, renal, hepatic,&#xD;
             pulmonary, gastrointestinal, neurological, endocrinological, immunological,&#xD;
             psychiatric or cardiovascular disease, myopathies, epileptic seizures and bleeding&#xD;
             tendency.&#xD;
&#xD;
          -  Recent myocardial infarct (within the last 3 months), unstable or deteriorating angina&#xD;
             pectoris, coronary artery vasospasm (Prinzmetal's angina), serious cardiac arrythmias&#xD;
             and acute stroke [added according to Amendment No. 1].&#xD;
&#xD;
          -  Use of any medication within 4 weeks prior to the first treatment or during the trial&#xD;
             which, in the opinion of the investigator, may influence the trial results or the&#xD;
             safety of the subjects.&#xD;
&#xD;
          -  Use of systemic or topical analgesics or antihistamines within 72 hours prior to trial&#xD;
             enrollment (except paracetamol) or systemic or topical corticosteroids within 3 weeks&#xD;
             of trial enrollment.&#xD;
&#xD;
          -  Subjects having used nicotine products other than cigarettes within the 3 months&#xD;
             preceding the trial&#xD;
&#xD;
          -  Subjects who cannot avoid, throughout the duration of the trial, any swimming, any&#xD;
             washing of the back and sauna or any intense physical activity that might result in&#xD;
             excessive sweating&#xD;
&#xD;
          -  Known sensitivity to adhesive tape&#xD;
&#xD;
          -  Known sensitivity to any component of the test products&#xD;
&#xD;
          -  History of irritation to topically applied products&#xD;
&#xD;
          -  Fissure or injury of the skin at the test area&#xD;
&#xD;
          -  Participation in the treatment phase of a clinical trial within 30 days prior to the&#xD;
             treatment phase of this trial or within 10 times the respective elimination half-life&#xD;
             of the investigational drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth Kruse, PhD</last_name>
    <role>Study Director</role>
    <affiliation>McNeil AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IKP GmbH</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>August 25, 2009</study_first_submitted>
  <study_first_submitted_qc>August 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2009</study_first_posted>
  <last_update_submitted>July 6, 2012</last_update_submitted>
  <last_update_submitted_qc>July 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

